Avacta Therapeutics

Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour microenvironment.

The company's delivery approach uses a short engineered peptide that masks the active payload until it is cleaved by fibroblast activation protein, a protease concentrated in tumour-supporting cells.

This mechanism concentrates drug activity at the tumour site while limiting systemic toxicity.

Two candidates are currently in clinical development across multiple solid tumour indications.